{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:05:25Z","timestamp":1790661925189,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Severe transaminitis during pregnancy represents a diagnostic challenge because multiple etiologies may coexist. We report a pregnant woman with suspected toxoplasmosis, intrahepatic cholestasis of pregnancy, and possible drug-induced liver injury who developed prolonged severe liver dysfunction despite extensive investigation and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 33-year-old primigravida was referred at 15 weeks' gestation because of positive Toxoplasma gondii serology and elevated liver enzymes (ALT\/AST 460\/150 U\/L). Despite treatment with spiramycin, later changed to pyrimethamine-based therapy, and ursodeoxycholic acid, liver injury progressed (ALT\/AST 1,363\/466 U\/L). Amniocentesis at 25 weeks showed negative T. gondii PCR. At 27 weeks, liver injury peaked (ALT\/AST 1,734\/728 U\/L); anti-SS-A\/Ro52 antibodies were detected, and bile acids subsequently increased to 82.4 \u03bcmol\/L. Extensive investigations excluded viral hepatitis and did not support autoimmune hepatitis, while serial fetal assessment and amniotic fluid PCR showed no evidence of congenital toxoplasmosis. The clinical picture was considered most consistent with multifactorial liver injury involving possible drug-induced hepatotoxicity and intrahepatic cholestasis of pregnancy in the setting of suspected toxoplasmosis. Labor was induced at 38 weeks. A healthy male infant (3,140\u2005g, Apgar scores 10\/10) was delivered vaginally. Three days postpartum, ALT\/AST decreased to 90\/57 U\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Severe transaminitis during pregnancy may have a multifactorial etiology, particularly when infectious, pregnancy-specific, medication-related, and immunological findings coexist. This case highlights the importance of careful differential diagnosis and multidisciplinary management when severe hepatocellular injury develops during pregnancy. Close maternal and fetal surveillance enabled the continuation of pregnancy to term, resulting in favorable maternal and neonatal outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1965005","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:37Z","timestamp":1790661037000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Severe persistent transaminitis during pregnancy: a complex differential diagnosis involving suspected toxoplasmosis, possible drug-induced liver injury, and intrahepatic cholestasis"],"prefix":"10.3389","volume":"13","author":[{"given":"\u017divil\u0117","family":"Sabonyt\u0117-Bal\u0161aitien\u0117","sequence":"first","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Volochovi\u010d","sequence":"additional","affiliation":[{"name":"Clinic of Obstetrics and Gynecology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cld.2018.12.013","article-title":"Liver diseases during pregnancy","volume":"23","author":"Ma","year":"2019","journal-title":"Clin Liver Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.12659\/MSM.907723","article-title":"Liver disease during pregnancy: a challenging clinical issue","volume":"24","author":"Mikolasevic","year":"2018","journal-title":"Med Sci Monit"},{"key":"B3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(24)02351-1","article-title":"Pregnancy and the liver","volume":"405","author":"Rahim","year":"2025","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2022.01.060","article-title":"Pregnancy-associated liver diseases","volume":"163","author":"Terrault","year":"2022","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.bpobgyn.2015.04.003","article-title":"Liver disease in pregnancy","volume":"29","author":"Geenes","year":"2015","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/cid\/cir667","article-title":"Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America","volume":"53","author":"Boyer","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/tropicalmed8010003","article-title":"Toxoplasmosis infection during pregnancy","volume":"8","author":"Deganich","year":"2023","journal-title":"Trop Med Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1756-3305-4-75","article-title":"Toxoplasma gondii infection and liver disease: a case-control study in a northern Mexican population","volume":"4","author":"Alvarado-Esquivel","year":"2011","journal-title":"Parasit Vectors"},{"key":"B9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejogrb.2020.10.003","article-title":"Toxoplasmosis in pregnancy","volume":"255","author":"Ahmed","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1590\/S0074-02761987000400005","article-title":"Epidemiological aspects of toxoplasmosis in schoolchildren residing in localities with urban or rural characteristics within the city of rio de janeiro, Brazil","volume":"82","author":"Souza","year":"1987","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"B11","first-page":"205","article-title":"Toxoplasmosis","volume-title":"Infectious Diseases of the fetus and Newborn Infant","author":"Remington","year":"2001"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/infdis\/jiac422","article-title":"TgMIF promotes hepatocyte pyroptosis and recruitment of proinflammatory macrophages during severe liver injury in acute toxoplasmosis","volume":"227","author":"Zhou","year":"2023","journal-title":"J Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/jac\/22.Supplement_B.207","article-title":"Spiramycin: safety in man","volume":"22","author":"Descotes","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ajg.2010.11.001","article-title":"Severe hepatotoxicity associated with the combination of spiramycin plus metronidazole","volume":"12","author":"Hussein","year":"2011","journal-title":"Arab J Gastroenterol"},{"key":"B15","article-title":"Sulfadoxine-pyrimethamine","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"Hoofnagle","year":"2012"},{"key":"B16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12887-023-04097-9","article-title":"Liver injury in children: signal analysis of suspected drugs based on the food and drug administration adverse event reporting system","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Pediatr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12969-023-00803-0","article-title":"Maternal and infant outcomes of pregnancy associated with anti-SSA\/ro antibodies: a systematic review and meta-analysis","volume":"21","author":"Sheng","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5455\/msm.2024.36.47-53","article-title":"Association of anti-ro\/SSA and anti-la\/SSB autoantibodies with pregnancy outcome in the general population","volume":"36","author":"Dragoutsos","year":"2024","journal-title":"Mater Sociomed"},{"key":"B19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12916-025-03935-0","article-title":"Global and regional incidence of intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis","volume":"23","author":"Jamshidi Kerachi","year":"2025","journal-title":"BMC Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1111\/1471-0528.17206","article-title":"Intrahepatic cholestasis of pregnancy: green-top guideline No. 43 June 2022","volume":"129","author":"Girling","year":"2022","journal-title":"BJOG"},{"key":"B21","article-title":"Pregnancy intrahepatic cholestasis","volume-title":"StatPearls","author":"Crites","year":"2026"},{"key":"B22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(18)31877-4","article-title":"Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses","volume":"393","author":"Ovadia","year":"2019","journal-title":"Lancet"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1965005\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:38Z","timestamp":1790661038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1965005\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":22,"alternative-id":["10.3389\/fmed.2026.1965005"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1965005","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1965005"}}